HARVARD BIOTECH INCUBATOR
The Harvard Biotech Incubator (HBI) focuses on developing and applying marketable skills and strategies to prepare students and postdoctoral fellows for successful careers in biotechnology. Our team collaborates with industry leaders to bring a novel idea or technology from the laboratory bench to the market. HBI members perform due diligence, develop products, craft business plans, and even pitch technologies to investors. The Incubator serves as hands-on, practical experience for curious and motivated students and postdocs.
ACADEMIC + INDUSTRY ADVISORS
Carl Novina, MD, PhD
Associate Professor, Dana-Farber Cancer Institute & Harvard Medical School
Associate Member, Broad Institute of Harvard and MIT
Fred Mermelstein, PhD
Entrepreneur in Residence at Dana Farber Cancer Institute
Chairman of the Board Pear Tree Pharmaceuticals, Inc.
Vice-Chairman of the Board Linus Oncology, Inc.
Member of the Boston Harbor Angels
Former CEO/President of Javelin Pharmaceuticals, Inc.
Robert Distel, PhD
Special Advisor for Technology Development, Dana Farber Cancer Institute
Former member of the Center for Clinical and Translational Research at Dana Farber
Former director of Dana Farber Translational Research Laboratory
Former Associate director of the Laboratory for Innovative Translational Technology, Harvard Catalyst
Epigenetic Reprogramming Platform Technology
Working with a modified Cas9 technology developed in Dr. Novina's laboratory, HBI members performed due diligence on genetic targets and indications and presented their findings. Product profile sheets were produced for the leading indications, and this spring we will begin drafting a business plan for this novel epigenetic engineering platform.
Cellular Immunotherapy for Treating Cancer and Autoimmune Diseases
.... NEW PROJECT FOR FALL 2017
Enteromics is a newly formed company that has acquired the worldwide intellectual property rights for the use of naturally occurring bacteria molecularly engineered for detection and treatment of diseases of the gastrointestinal (GI) tract. Enteromics’ strategy is to modify bacterial membranes with specific proteins that bind specifically to diseased tissues sparing normal healthy tissue. Enteromics’ bacteria are further modified to carry a wide range of payloads such as light-emitting molecules for direct visualization; non-invasive imaging dyes for virtual imaging including PET, CT and MRI scanning; molecules that modulate inflammatory states; and chemotherapeutic compounds. Enteromics’ platform technology enables detection, imaging and treatment of a wide range of conditions caused by inflammation, erosion, abnormal cell growth, and cancer.
HBI will be accepting new team members for fall 2017.
For more information please contact: email@example.com
NEXT MEETING: Fall 2017 HBI Info Session